{"id":"nct:NCT05556720","kind":"trial","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","authors":["Monash University"],"author_count":1,"year":2022,"published":"2022-09-27","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05556720","source_url":"https://clinicaltrials.gov/study/NCT05556720","archive_url":"https://space-kitty.com/papers/nct:NCT05556720","updated":"2025-10-03","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"Despite the greater risk of adverse COVID-19 outcomes, antibody and cell-mediated immune responses to COVID-19 vaccines vary amongst immunocompromised (IC) people and are poorly defined. IC hosts were largely excluded from the COVID-19 vaccine registration trials, though many countries recommend additional and booster doses of vaccination in this group. BOOST-IC is an adaptive randomised clinical trial (RCT) to assess the immunogenicity and safety of additional COVID-19 vaccine doses in immunocompromised (IC) people, including people with HIV, solid organ transplants (SOT) recipients or those with haematological malignancies. Briefly, the study aims to generate high-quality evidence on the immunogenicity and safety of alternative COVID-19 booster strategies against SARS-CoV-2 for IC people in Australia.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["HIV","Organ Transplantation","Lymphoma, Non-Hodgkin","Chronic Lymphocytic Leukemia","Multiple Myeloma","COVID-19 Vaccines"],"details":{"acronym":"BOOST-IC","status":"ACTIVE_NOT_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":960,"sponsor":"Monash University","conditions":["HIV","Organ Transplantation","Lymphoma, Non-Hodgkin","Chronic Lymphocytic Leukemia","Multiple Myeloma","COVID-19 Vaccines"],"interventions":["BIOLOGICAL: Pfizer Bivalent COVID-19 Vaccine","BIOLOGICAL: Moderna Bivalent mRNA vaccine"],"start_date":"2022-12-01","start_date_type":"ACTUAL","primary_completion_date":"2026-06-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}